Wells Fargo analyst David Maris says FDA approval of solriamfetol for excessive sleepiness associated with narcolepsy or obstructive sleep apnea, while largely expected by investors, is still a "nice win" for shares of Jazz Pharmaceuticals. The analyst estimates sales for solriamfetol of approximately $12M in 2019, ramping to $371M by 2023. Maris reiterates an Outperform rating on Jazz with a $154 price target. Additional potential catalysts for the stock include the Xyrem launch for pediatric indication in late Q1, JZP258 topline results for a Phase 3 study in narcolepsy in Spring 2019, and any update on the business development front, Maris tells investors in a research note. Jazz in midday trading is up 3%, or $3.45, to $137.02.